Affective outcomes of virtual reality exposure therapy for anxiety and specific phobias: A meta-analysis

Parsons, Thomas D.; Rizzo, Albert

doi:10.1016/j.jbtep.2007.07.007

Cited by 818 publications

(461 citation statements)

References 45 publications

Supporting

Mentioning

431

Contrasting

Unclassified

Order By: Relevance

“…The VRE-DCS group also continued to improve on all measures after treatment ended. This is especially impressive given that both groups received an active psychotherapy with documented efficacy for the treatment of terroristrelated chronic PTSD (Difede et al, 2007;Parsons and Rizzo, 2008). In addition, PTSD symptom clusters B (re-experiencing), C (avoidance), and D (hyperarousal) in the VRE-DCS group showed significant improvement compared with the VRE-placebo group.…”

Section: Discussionmentioning

confidence: 95%

D-Cycloserine Augmentation of Exposure Therapy for Post-Traumatic Stress Disorder: A Pilot Randomized Clinical Trial

Difede

Cukor

Wyka

et al. 2013

Neuropsychopharmacol

198

135

View full text Add to dashboard Cite

Viewing post-traumatic stress disorder (PTSD) as a disorder of emotional learning, this study used a cognitive enhancer synergistically with virtual reality exposure (VRE) therapy for the treatment of PTSD. The main objective was to determine if a novel pharmacotherapy, D-cycloserine (DCS), enhanced the efficacy of the psychotherapy. Pre-clinical studies suggest that when fear extinction occurs during DCS administration, neuroplasticity may be enhanced. VRE therapy is a particularly promising format to test the hypothesis that DCS enhances extinction learning, as sensory fear cues are standardized across patients. In a pilot randomized, double-blind, placebocontrolled trial, 100 mg of DCS or placebo was administered 90 min before each weekly VRE session, to ensure peak plasma concentrations during the sessions in 25 patients with chronic PTSD. The primary outcome measure was the Clinician Administered PTSD Scale (CAPS). Secondary outcome measures included the Beck Depression Inventory-II and the State-Trait Anger Expression Inventory-2. Assessments occurred at pre-treatment, following sessions 3, 6, 10, post-treatment, and at 6 months. The difference in CAPS between the VRE-DCS (n ¼ 13) and VRE-placebo (n ¼ 12) groups increased over time beginning at 6 weeks, with medium to large between-group effect sizes immediately post-treatment and 6 months later (d ¼ 0.68 and d ¼ 1.13, respectively). A similar pattern was observed for depression, anger expression, and sleep. PTSD remission rates were significantly greater for the VRE-DCS group (46% vs 8% at post-treatment; 69% vs 17% at 6 months). Patients in the VRE-DCS group showed earlier and greater improvement in PTSD symptoms compared with the VRE-placebo group. These results suggest a promising new treatment for PTSD.

show abstract

Section: Discussionmentioning

confidence: 95%

D-Cycloserine Augmentation of Exposure Therapy for Post-Traumatic Stress Disorder: A Pilot Randomized Clinical Trial

Difede

Cukor

Wyka

et al. 2013

Neuropsychopharmacol

198

135

View full text Add to dashboard Cite

show abstract

“…This recognition of the potential impact of VR technology has led to the emergence of a significant, albeit still maturing, research literature that documents the many clinical and research targets where VR can add value relative to traditional assessment and intervention methods. A short list of the areas where Clinical VR has been usefully applied includes fear reduction in persons with specific phobias (Morina et al, 2015; Opris et al, 2012; Parsons & Rizzo, 2008; Powers & Emmelkamp, 2008), treatment for posttraumatic stress disorder (Beidel, Frueh, Neer, & Lejuez, 2017; Botella et al, 2015; Difede & Hoffman, 2002; Difede et al, 2007, 2014; Maples-Keller et al, 2017; McLay et al, 2011; Rizzo et al, 2010, 2013, 2017; Rothbaum, Hodges, Ready, Graap, & Alarcon, 2001; Rothbaum et al, 2014), cue-exposure for addiction and relapse prevention (Hone-Blanchet, Wensing, & Fecteau, 2014; Yoon et al, 2014), depression (Falconer et al, 2016), paranoid delusions (Freeman et al, 2016), discomfort reduction in cancer patients undergoing chemotherapy (Schneider, Kisby, & Flint, 2010), acute pain reduction during wound care and physical therapy with burn patients (Hoffman et al, 2011), other painful procedures (Gold et al, 2006; Mosadeghi, Reid, Martinez, Rosen, & Spiegel, 2016), body image disturbances in patients with eating disorders (Riva, 2011), navigation and spatial training in children and adults with motor impairments (John, Pop, Day, Ritsos, & Headleand, 2017), functional skill training and motor rehabilitation in patients with central nervous system dysfunction (e.g. stroke, traumatic brain injury, spinal cord injury, cerebral palsy, multiple sclerosis, etc.)…”

Section: Introductionmentioning

confidence: 99%

Clinical Virtual Reality tools to advance the prevention, assessment, and treatment of PTSD

Rizzo

Shilling

2017

European Journal of Psychotraumatology

152

107

View full text Add to dashboard Cite

Numerous reports indicate that the incidence of posttraumatic stress disorder (PTSD) in Operation Enduring Freedom/Operation Iraqi Freedom/Operation New Dawn (OEF/OIF/OND) military personnel has created a significant behavioural healthcare challenge. These findings have served to motivate research on how to better develop and disseminate evidence-based treatments for PTSD. The current article presents the use of Virtual Reality (VR) as a clinical tool to address the assessment, prevention, and treatment of PTSD, based on the VR projects that were evolved at the University of Southern California Institute for Creative Technologies since 2004. A brief discussion of the definition and rationale for the clinical use of VR is followed by a description of a VR application designed for the delivery of prolonged exposure (PE) for treating Service Members (SMs) and Veterans with combat- and sexual assault-related PTSD. The expansion of the virtual treatment simulations of Iraq and Afghanistan for PTSD assessment and prevention is then presented. This is followed by a forward-looking discussion that details early efforts to develop virtual human agent systems that serve the role of virtual patients for training the next generation of clinical providers, as healthcare guides that can be used to support anonymous access to trauma-relevant behavioural healthcare information, and as clinical interviewers capable of automated behaviour analysis of users to infer psychological state. The paper will conclude with a discussion of VR as a tool for breaking down barriers to care in addition to its direct application in assessment and intervention.

show abstract

“…El ácido valproico también podría ser útil 33 . En cualquier caso, estos y otros tratamientos experimentales, como la realidad virtual 30 , deberían ser indicados por exTabla 4. Síntomas de TEPT el tePt se caracteriza por la presencia de tres grupos de síntomas que deben estar presentes por al menos un mes.…”

Section: Nivel V Manejo Psiquiátrico Por Expertosunclassified

Apoyo psicológico en desastres: Propuesta de un modelo de atención basado en revisiones sistemáticas y metaanálisis

Figueroa¹,

Marín²,

González³

2010

Rev. méd. Chile

View full text Add to dashboard Cite

show abstract

Affective outcomes of virtual reality exposure therapy for anxiety and specific phobias: A meta-analysis

Cited by 818 publications

References 45 publications

D-Cycloserine Augmentation of Exposure Therapy for Post-Traumatic Stress Disorder: A Pilot Randomized Clinical Trial

D-Cycloserine Augmentation of Exposure Therapy for Post-Traumatic Stress Disorder: A Pilot Randomized Clinical Trial

Clinical Virtual Reality tools to advance the prevention, assessment, and treatment of PTSD

Apoyo psicológico en desastres: Propuesta de un modelo de atención basado en revisiones sistemáticas y metaanálisis

Contact Info

Product

Resources

About